Brokerage Firm Rating on RTI Surgical (RTIX)

RTI Surgical (RTIX) : 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on RTI Surgical (RTIX). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 2 Wall Street Analysts endorse the stock as a Hold with a rating of 3.


Company shares have received an average consensus rating of Hold for the current week RTI Surgical (NASDAQ:RTIX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.11 and $3.11 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.11, notching a gain of 0.32% for the day. The total traded volume was 53,228 . The stock had closed at $3.10 on the previous day.

RTI Surgical, Inc. produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company uses natural tissues, metals and synthetics process to produce its products. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Companys business has six categories: spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), surgical specialties and dental. The Company distributes its implants and services in all 50 states and in over 45 countries worldwide.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.